Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.